GLOBEALERT
HEALTHLOWJul 29 · Jul 29, 2026, 5:47 PM

Allogene rises as FDA offers Fast Track, RMAT tags to cell therapy

Seeking Alpha Tech

Allogene's stock rose after the FDA granted Fast Track and RMAT designations to its cell therapy. This indicates expedited regulatory review for a potentially significant medical treatment.

GlobeAlert aggregates and classifies open sources; the story above belongs to its publisher. Summaries are machine-generated from the source text.

More in Health